Abstract Details

Title A Brief Look at Urgent Care Visits for Migraine: the Care Received and Ideas to Guide Migraine Care in this Proliferating Medical Setting

Topic Headache

Presentation(s) P12 - Poster Session 12 (12:00 PM-1:00 PM)

Poster/Presentation
Number 7-002

Objective We sought to examine the use of urgent care visits for migraine, and trends in management of migraine in these urgent cares.

Background There is a huge rise of urgent care centers in the US. It is unknown how people with migraine are being managed in urgent cares.

Design/Methods

We conducted a retrospective chart review of patients with migraine diagnoses at two urgent cares within one large urban medical center. We determined baseline patient demographics, migraine characteristics, frequencies and reasons for urgent care visits, medications administered and prescribed on discharge, and healthcare utilization post-discharge.

Results Of the 78 patients who visited urgent care with a migraine diagnosis, 25.6% had a known primary care provider within the urgent care centers’ healthcare system, and 78.2% had a history of either headache/migraine prior to the urgent care visit. Of those with a documented frequency of prior headaches, 94.1% (32/34) had episodic migraine and 79.4% (27/34) had 1-2 headache days/month. Of those having a migraine episode, 12.3% (9/73) were given intravenous metoclopramide. None were given subcutaneous sumatriptan or intravenous prochlorperazine. Of those with reported nausea or vomiting with their migraine, 46.2% (18/39) received an anti-emetic at the visit and 33.3% (13/39) were given an anti-emetic prescription. Only 11.1% (6/54) of patients who did not have a record of previous triptan use were given a triptan prescription at the urgent care visit.

Conclusions Most of the patients were not established patients within the urgent care centers’ healthcare system. Very few 12.3% (9/73) of those in pain were administered medications with the highest level of evidence by the American Headache Society (Level B) and most were not given triptans or anti-emetics on discharge. Having these migraine-specific prescriptions may enable improved self-treatment at home should a migraine attack recur.

Authors/Disclosures
Kina Zhou PRESENTER	No disclosure on file
	No disclosure on file
Mia T. Minen, MD, F�鶹��ýӳ�� (NYULMC Neurology)	The institution of Dr. Minen has received research support from NIH. Dr. Minen has received intellectual property interests from a discovery or technology relating to health care. Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a First Contact-Primary Care Advisory Board Member with American Headache Society . Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PCORI grant on migraine evidence based map for stakeholders with ECRI .

�鶹��ýӳ��

�鶹��ýӳ��